Back to Browse Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Issue 1

Arginine deprivation therapy for malignant melanoma

Authors Yoon JK, Frankel AE, Feun LG, Ekmekcioglu S, Kim KB

Published Date December 2012 Volume 2013:5(1) Pages 11—19

DOI http://dx.doi.org/10.2147/CPAA.S37350

Received 25 August 2012, Accepted 16 October 2012, Published 27 December 2012

Jung-Ki Yoon,1,2 Arthur E Frankel,3 Lynn G Feun,4 Suhendan Ekmekcioglu,1 Kevin B Kim1

1Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 2Hwasung Public Health Center, Hwasung, South Korea, 3Scott and White Cancer Research Institute, Temple, TX, USA; 4Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA

Abstract: Despite recent development of promising immunotherapeutic and targeted drugs, prognosis in patients with advanced melanoma remains poor, and a cure for this disease remains elusive in most patients. The success of melanoma therapy depends on a better understanding of the biology of melanoma and development of drugs that effectively target the relevant genes or proteins essential for tumor cell survival. Melanoma cells frequently lack argininosuccinate synthetase, an essential enzyme for arginine synthesis, and as a result they become dependent on the availability of exogenous arginine. Accordingly, a therapeutic approach involving depletion of available arginine has been shown to be effective in preclinical studies. Early clinical studies have demonstrated sufficient antitumor activity to give rise to cautious optimism. In this article, the rationale for arginine deprivation therapy is discussed. Additionally, various strategies for depleting arginine are discussed and the preclinical and clinical investigations of arginine deprivation therapy in melanoma are reviewed.

Keywords: arginine deprivation, argininosuccinate synthetase, melanoma

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Effect of statin therapy on vaspin levels in type 2 diabetic patients

Al-Azzam SI, Alzoubi KH, Abu Abeeleh J, Mhaidat NM, Abu-Abeeleh M

Clinical Pharmacology: Advances and Applications 2013, 5:33-38

Published Date: 20 February 2013

Nortriptyline versus fluoxetine in the treatment of major depressive disorder: a six-month, double-blind clinical trial

Hashemi SN, Ghafarian Shirazi HR, Mohammadi A, Zadeh-Bagheri GH, Noorian KH, Malekzadeh M

Clinical Pharmacology: Advances and Applications 2012, 4:1-6

Published Date: 27 January 2012

Drug-resistant tuberculosis: emerging treatment options

Adhvaryu MR, Vakharia BC

Clinical Pharmacology: Advances and Applications 2011, 3:51-67

Published Date: 14 December 2011

A case of cephalothin-associated urolithiasis

Ivan WM Lim, Peter JO Stride, Robert L Horvath

Clinical Pharmacology: Advances and Applications 2011, 3:1-3

Published Date: 28 February 2011

Chronomodulated press-coated pulsatile therapeutic system for aceclofenac: optimization of factors influencing drug release and lag time

Sumit Patil, Swati Pund, Amita Joshi, et al

ChronoPhysiology and Therapy 2011, 1:1-10

Published Date: 21 February 2011

Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review

Christina Southern Reh, Mitchell E Geffner

Clinical Pharmacology: Advances and Applications 2010, 2:111-122

Published Date: 1 June 2010

Targeting colorectal cancer with human anti-EGFR monoclonocal antibodies: focus on panitumumab

George P Kim, Axel Grothey

Biologics: Targets and Therapy 2008, 2:223-228

Published Date: 30 June 2008